{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T21:29:09Z","timestamp":1792790949445,"version":"4.5.0"},"reference-count":30,"publisher":"American Medical Association (AMA)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"\n Importance<\/jats:title>\n The cumulative burden of chronic vascular and neurodegenerative changes contributes to brain frailty, which may reduce the brain\u2019s capacity to recover from acute ischemic stroke (AIS). The association between brain frailty markers and poststroke outcomes after thrombolysis is unclear.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To evaluate associations between brain frailty assessed on non\u2013contrast-enhanced computed tomography (NCCT) and magnetic resonance imaging (MRI) and functional outcome in patients with AIS treated with intravenous thrombolysis.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n This cohort study was a post hoc analysis of the Alteplase compared to Tenecteplase (AcT) trial, an investigator-led, registry-linked, parallel-group, open-label, randomized clinical trial that enrolled patients between December 10, 2019, and January 25, 2022, at 22 primary and comprehensive stroke centers across Canada. Participants included adults 18 years or older diagnosed with ischemic stroke causing disabling neurological deficit, presenting within 4.5 hours of symptom onset, and meeting Canadian guidelines for thrombolysis. Markers of brain frailty (cortical and subcortical atrophy, white matter changes [Fazekas score, grouped as 0, 1-2, and 3-6], lacunes, chronic infarctions, and [on MRI] microbleeds, siderosis, and enlarged perivascular spaces) were retrospectively assessed while reviewers were blinded to outcome variables. Analyses were performed from July 24, 2024, to March 25, 2025.<\/jats:p>\n <\/jats:sec>\n \n Exposures<\/jats:title>\n Patients underwent baseline NCCT and were randomized to receive intravenous thrombolysis with alteplase (0.9 mg\/kg) or tenecteplase (0.25 mg\/kg). Some patients also received posttreatment brain MRI.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n The primary outcome was excellent functional outcome (modified Rankin Scale [mRS] score of 0-1) at 90 days. Secondary outcomes included 90-day ordinal mRS score (trichotomized as 0-2, 3-4, and 5-6), symptomatic intracerebral hemorrhage, and mortality. Sensitivity analyses were performed in patients with available MRI scans.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n Among the 1568 patients (median age, 74 [IQR, 63-83] years; 817 male [52.1%]) with interpretable NCCT findings, after correcting for multiple comparisons, higher total Fazekas score of 3 to 6 compared with 0 was associated with lower odds of a 90-day mRS score of 0 to 1 (adjusted odds ratio [OR],\u20090.40 [95% CI, 0.24-0.65]). Total Fazekas score (adjusted common OR [ACOR],\u20092.80 [95% CI, 1.88-4.16]), cortical atrophy (ACOR,\u20092.65 [95% CI. 1.63-4.32]), and total brain frailty score (ACOR,\u20093.15 [95% CI, 1.87-5.33]) were each associated with worse ordinal mRS, but were not associated with safety outcomes.<\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n In this cohort study of patients with AIS treated with intravenous thrombolysis, brain frailty markers\u2014particularly white matter changes, cortical atrophy, and total brain frailty\u2014were associated with worse outcomes. Consideration of these neuroimaging markers may better inform clinicians and patients about treatment expectations from thrombolytic therapy.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2025.34941","type":"journal-article","created":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T15:30:21Z","timestamp":1759246221000},"page":"e2534941","source":"Crossref","is-referenced-by-count":21,"title":["Brain Frailty and Functional Outcomes After Thrombolysis for Acute Ischemic Stroke"],"prefix":"10.1001","volume":"8","author":[{"given":"Spencer P.","family":"Loewen","sequence":"first","affiliation":[{"name":"Calgary Stroke Program, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nishita","family":"Singh","sequence":"additional","affiliation":[{"name":"Neurology Section, Department of Internal Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ibrahim","family":"Alhabli","sequence":"additional","affiliation":[{"name":"Department of Clinical Neurosciences, the Hotchkiss Brain Institute and the O\u2019Brien Institute for Public Health, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada"},{"name":"Department of Radiology, the Hotchkiss Brain Institute and the O\u2019Brien Institute for Public Health, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada"},{"name":"Department of Community Health Sciences, the Hotchkiss Brain Institute and the O\u2019Brien Institute for Public Health, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fouzi","family":"Bala","sequence":"additional","affiliation":[{"name":"Diagnostic and Interventional Neuroradiology Department, University Hospital of Tours, Tours, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Buck","sequence":"additional","affiliation":[{"name":"Division of Neurology, Department of Medicine, University of Alberta, Edmonton, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faysal","family":"Benali","sequence":"additional","affiliation":[{"name":"Department of Radiology, AZ Vesalius, Tongeren, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Betzner","sequence":"additional","affiliation":[{"name":"Calgary Stroke Program, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada"},{"name":"Department of Clinical Neurosciences, the Hotchkiss Brain Institute and the O\u2019Brien Institute for Public Health, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaden","family":"Lam","sequence":"additional","affiliation":[{"name":"Calgary Stroke Program, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada"},{"name":"Graduate Science Education, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luciana","family":"Catanese","sequence":"additional","affiliation":[{"name":"Department of Medicine, McMaster University and Population Health Research Institute, Hamilton, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksander","family":"Tkach","sequence":"additional","affiliation":[{"name":"Kelowna General Hospital, Kelowna, British Columbia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dar","family":"Dowlatshahi","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Ottawa and Ottawa Hospital Research Institute, Ottawa, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Carpani","sequence":"additional","affiliation":[{"name":"Department of Neurology, Toronto Western Hospital and the University of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thalia S.","family":"Field","sequence":"additional","affiliation":[{"name":"Department of Neurosciences, University of British Columbia, Vancouver, British Columbia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary","family":"Hunter","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Saskatchewan, Saskatoon, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Houman","family":"Khosravani","sequence":"additional","affiliation":[{"name":"Neurology Division, Department of Medicine, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksandra","family":"Pikula","sequence":"additional","affiliation":[{"name":"Department of Neurology, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Shamy","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Ottawa and Ottawa Hospital Research Institute, Ottawa, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tolulope T.","family":"Sajobi","sequence":"additional","affiliation":[{"name":"Department of Clinical Neurosciences, the Hotchkiss Brain Institute and the O\u2019Brien Institute for Public Health, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed","family":"Almekhlafi","sequence":"additional","affiliation":[{"name":"Department of Clinical Neurosciences, the Hotchkiss Brain Institute and the O\u2019Brien Institute for Public Health, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rick","family":"Swartz","sequence":"additional","affiliation":[{"name":"Neurology Division, Department of Medicine, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bijoy","family":"Menon","sequence":"additional","affiliation":[{"name":"Department of Clinical Neurosciences, the Hotchkiss Brain Institute and the O\u2019Brien Institute for Public Health, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahesh","family":"Kate","sequence":"additional","affiliation":[{"name":"Department of Community Health Sciences, the Hotchkiss Brain Institute and the O\u2019Brien Institute for Public Health, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aravind","family":"Ganesh","sequence":"additional","affiliation":[{"name":"Department of Clinical Neurosciences, the Hotchkiss Brain Institute and the O\u2019Brien Institute for Public Health, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2025,9,30]]},"reference":[{"issue":"5","key":"zoi250975r1","doi-asserted-by":"publisher","first-page":"1514","DOI":"10.1161\/STROKEAHA.119.028511","article-title":"Brain atrophy and the risk of futile endovascular reperfusion in acute ischemic stroke.","volume":"51","author":"Pedraza","year":"2020","journal-title":"Stroke"},{"issue":"5","key":"zoi250975r2","doi-asserted-by":"publisher","first-page":"e439","DOI":"10.1212\/WNL.0000000000008881","article-title":"Imaging markers of small vessel disease and brain frailty, and outcomes in acute stroke.","volume":"94","author":"Appleton","year":"2020","journal-title":"Neurology"},{"issue":"7","key":"zoi250975r4","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1016\/S1474-4422(23)00131-X","article-title":"Neuroimaging standards for research into small vessel disease-advances since 2013.","volume":"22","author":"Duering","year":"2023","journal-title":"Lancet Neurol"},{"issue":"14","key":"zoi250975r5","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1212\/WNL.0000000000000837","article-title":"Stroke subtype, vascular risk factors, and total MRI brain small-vessel disease burden.","volume":"83","author":"Staals","year":"2014","journal-title":"Neurology"},{"issue":"24","key":"zoi250975r6","doi-asserted-by":"publisher","first-page":"2260","DOI":"10.1212\/WNL.0000000000004042","article-title":"Total small vessel disease score and risk of recurrent stroke: validation in 2 large cohorts.","volume":"88","author":"Lau","year":"2017","journal-title":"Neurology"},{"issue":"1","key":"zoi250975r7","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1111\/ane.12745","article-title":"Small vessel disease and clinical outcomes after IV rt-PA treatment.","volume":"136","author":"Arba","year":"2017","journal-title":"Acta Neurol Scand"},{"issue":"10347","key":"zoi250975r8","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/S0140-6736(22)01054-6","article-title":"Intravenous tenecteplase compared with alteplase for acute ischaemic stroke in Canada (AcT): a pragmatic, multicentre, open-label, registry-linked, randomised, controlled, non-inferiority trial.","volume":"400","author":"Menon","year":"2022","journal-title":"Lancet"},{"issue":"5","key":"zoi250975r10","doi-asserted-by":"publisher","DOI":"10.1161\/SVIN.122.000447","article-title":"AcT Trial: protocol for a pragmatic registry-linked randomized clinical trial.","volume":"2","author":"Sajobi","year":"2022","journal-title":"Stroke Vasc Intervent Neurol"},{"issue":"5","key":"zoi250975r11","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1159\/000117270","article-title":"Inter- and intraobserver reproducibility of cerebral atrophy assessment on MRI scans with hemispheric infarcts.","volume":"36","author":"Pasquier","year":"1996","journal-title":"Eur Neurol"},{"issue":"2","key":"zoi250975r12","doi-asserted-by":"publisher","first-page":"351","DOI":"10.2214\/ajr.149.2.351","article-title":"MR signal abnormalities at 1.5 T in Alzheimer\u2019s dementia and normal aging.","volume":"149","author":"Fazekas","year":"1987","journal-title":"AJR Am J Roentgenol"},{"issue":"12","key":"zoi250975r13","doi-asserted-by":"publisher","first-page":"2454","DOI":"10.1177\/0271678X19893600","article-title":"Severity of white matter hyperintensities: lesion patterns, cognition, and microstructural changes.","volume":"40","author":"Zeng","year":"2020","journal-title":"J Cereb Blood Flow Metab"},{"issue":"pt 1","key":"zoi250975r14","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1348\/000711006X126600","article-title":"Computing inter-rater reliability and its variance in the presence of high agreement.","volume":"61","author":"Gwet","year":"2008","journal-title":"Br J Math Stat Psychol"},{"issue":"10","key":"zoi250975r15","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.3174\/ajnr.A7981","article-title":"Cortical and subcortical brain atrophy assessment using simple measures on NCCT compared with MRI in acute stroke.","volume":"44","author":"Jaroenngarmsamer","year":"2023","journal-title":"AJNR Am J Neuroradiol"},{"issue":"10","key":"zoi250975r16","doi-asserted-by":"publisher","first-page":"2981","DOI":"10.1161\/STROKEAHA.115.010049","article-title":"The Heidelberg Bleeding Classification: classification of bleeding events after ischemic stroke and reperfusion therapy.","volume":"46","author":"von Kummer","year":"2015","journal-title":"Stroke"},{"issue":"1","key":"zoi250975r17","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.49628","article-title":"Mediation of age and thrombectomy outcome by neuroimaging markers of frailty in patients with stroke.","volume":"7","author":"Benali","year":"2024","journal-title":"JAMA Netw Open"},{"issue":"8","key":"zoi250975r18","doi-asserted-by":"publisher","first-page":"2084","DOI":"10.1161\/STROKEAHA.116.012992","article-title":"Microbleeds, cerebral hemorrhage, and functional outcome after stroke thrombolysis.","volume":"48","author":"Charidimou","year":"2017","journal-title":"Stroke"},{"issue":"7","key":"zoi250975r19","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1212\/WNL.0000000000003605","article-title":"Leukoaraiosis, intracerebral hemorrhage, and functional outcome after acute stroke thrombolysis.","volume":"88","author":"Kongbunkiat","year":"2017","journal-title":"Neurology"},{"issue":"5","key":"zoi250975r20","doi-asserted-by":"publisher","first-page":"e204","DOI":"10.1161\/STR.0000000000000406","article-title":"Endovascular treatment and thrombolysis for acute ischemic stroke in patients with premorbid disability or dementia: a scientific statement from the American Heart Association\/American Stroke Association.","volume":"53","author":"Ganesh","year":"2022","journal-title":"Stroke"},{"issue":"5","key":"zoi250975r21","doi-asserted-by":"publisher","DOI":"10.1161\/SVIN.123.000866","article-title":"Cerebral small vessel disease and outcomes in patients with acute ischemic stroke receiving endovascular treatment: a systematic review and meta-analysis.","volume":"3","author":"Kong","year":"2023","journal-title":"Stroke Vasc Intervent Neurol"},{"issue":"3","key":"zoi250975r22","doi-asserted-by":"publisher","first-page":"e302","DOI":"10.1212\/WNL.0000000000013055","article-title":"Cerebral microbleeds and treatment effect of intravenous thrombolysis in acute stroke: an analysis of the WAKE-UP randomized clinical trial.","volume":"98","author":"Schlemm","year":"2022","journal-title":"Neurology"},{"issue":"7","key":"zoi250975r23","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.1016\/j.jstrokecerebrovasdis.2017.03.002","article-title":"Cerebral white matter hypoperfusion increases with small-vessel disease burden: data from the Third International Stroke Trial.","volume":"26","author":"Arba","year":"2017","journal-title":"J Stroke Cerebrovasc Dis"},{"issue":"10","key":"zoi250975r24","doi-asserted-by":"publisher","first-page":"6943","DOI":"10.1007\/s00330-022-08792-6","article-title":"Beyond collaterals: brain frailty additionally improves prediction of clinical outcome in acute ischemic stroke.","volume":"32","author":"Zhou","year":"2022","journal-title":"Eur Radiol"},{"issue":"1","key":"zoi250975r25","doi-asserted-by":"publisher","first-page":"9210","DOI":"10.1038\/s41598-020-66013-w","article-title":"Network localisation of white matter damage in cerebral small vessel disease.","volume":"10","author":"Petersen","year":"2020","journal-title":"Sci Rep"},{"issue":"6","key":"zoi250975r26","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.117.005788","article-title":"Time course of evolution of disability and cause-specific mortality after ischemic stroke: implications for trial design.","volume":"6","author":"Ganesh","year":"2017","journal-title":"J Am Heart Assoc"},{"key":"zoi250975r27","doi-asserted-by":"publisher","first-page":"275","DOI":"10.3389\/fneur.2017.00275","article-title":"Pre-Stroke modified Rankin Scale: evaluation of validity, prognostic accuracy, and association with treatment.","volume":"8","author":"Quinn","year":"2017","journal-title":"Front Neurol"},{"issue":"12","key":"zoi250975r28","doi-asserted-by":"publisher","first-page":"3184","DOI":"10.1161\/STROKEAHA.112.670422","article-title":"Prestroke modified Rankin Stroke Scale has moderate interobserver reliability and validity in an acute stroke setting.","volume":"43","author":"Fearon","year":"2012","journal-title":"Stroke"},{"issue":"1","key":"zoi250975r29","doi-asserted-by":"publisher","first-page":"72","DOI":"10.5853\/jos.2022.02880","article-title":"Replacing alteplase with tenecteplase: is the time ripe?","volume":"25","author":"Singh","year":"2023","journal-title":"J Stroke"},{"issue":"10377","key":"zoi250975r30","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1016\/S0140-6736(22)02600-9","article-title":"Tenecteplase versus alteplase in acute ischaemic cerebrovascular events (TRACE-2): a phase 3, multicentre, open-label, randomised controlled, non-inferiority trial.","volume":"401","author":"Wang","year":"2023","journal-title":"Lancet"},{"key":"zoi250975r3","doi-asserted-by":"crossref","unstructured":"IST-3 Collaborative Group. Association between brain imaging signs, early and late outcomes, and response to intravenous alteplase after acute ischaemic stroke in the third International Stroke Trial (IST-3): secondary analysis of a randomised controlled trial.? Lancet Neurol. 2015;14(5):485-496. doi:10.1016\/S1474-4422(15)00012-5","DOI":"10.1016\/S1474-4422(15)00012-5"},{"key":"zoi250975r9","unstructured":"Alteplase Compared to Tenecteplase in Patients With Acute Ischemic Stroke (AcT). ClinicalTrials.gov Identifier NCT03889249. Updated May 12, 2023. Accessed May 25, 2025. https:\/\/clinicaltrials.gov\/study\/NCT03889249"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2839478\/loewen_2025_oi_250975_1758638225.49055.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T15:30:24Z","timestamp":1759246224000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2839478"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,30]]},"references-count":30,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9,2]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2025.34941","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,30]]}}}